A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

The Ensign Group Acquires Post-Acute Care Campus in Arizona

The Ensign Group, Inc., the parent company of the EnsignTM group of companies, which provide skilled nursing and assisted living services, physical, occupational and speech therapies and other rehabilitative and healthcare services, announced today (August 3, 2020) that it acquired the real estate and operations of a post-acute care retirement campus located in Tempe, AZ.

The acquisition was effective August 1, 2020.  The acquisition includes Tempe Post Acute, a 62-bed skilled nursing facility and Desert Marigold Senior Living of Tempe a senior living center with 72 assisted living beds and 90 independent living units.

“We are very excited to add this well-respected healthcare campus to our mature operations in the greater Phoenix market” said Barry Port, Ensign’s Chief Executive Officer. “As our first transaction since the COVID pandemic arrived at our door steps, our local leadership team in Arizona has taken extra precautions and have implemented a care plan to meet the needs of patients while closely following local and state guidelines.   We have full confidence in our team’s ability to add this operation in the midst of a pandemic and look forward to working with our new team,” he added.

“This is a unique time to add an operation but our local team of clinical and operational leaders are amongst our most experienced transition teams that have participated in many acquisitions in Arizona,” said Forrest Peterson, President of Bandera Healthcare LLC, Ensign’s Arizona-based subsidiary.  “We are also very impressed with the talented group of caregivers at these operations and look forward to working together to enhance the clinical outcomes and to take this operation to new heights,” he added.

These acquisitions bring Ensign’s growing portfolio to 226 healthcare operations, 24 of which also include assisted living operations, across thirteen states.  Ensign owns the real estate at 92 healthcare operations.  Mr. Port reaffirmed that Ensign is actively seeking opportunities to acquire real estate and to lease both well-performing and struggling skilled nursing, assisted living and other healthcare related businesses throughout the United States.

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
The partnership is with Health-HavenRx ™, an online pharmacy platform. This partnership enables a new, convenient channel for patients to access POGO Automatic by using their health insurance on Intuity Medical’s e-commerce website at www.GoodtoPogo.com.

By using this website you agree to accept Medical Device News Magazine Privacy Policy